Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment

Pharmacogenomics

Volumn 17, Issue 3, 2016, Pages 297-307

  Cheung, Lydia Wt ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

MAPK; mutation; p85; PI3K; PIK3R1; targeted therapy

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AEG 3482; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BI 78D 3; DACTOLISIB; ERLOTINIB; GSK 2126458A; HISTONE DEACETYLASE INHIBITOR; HYPOTHEMYCIN; IDELALISIB; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHENMETRAZINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; SELUMETINIB; TEMSIROLIMUS; TGX 221; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3R1 PROTEIN, HUMAN; PROTEIN BINDING;

BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; DIMERIZATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME INHIBITION; GENE MUTATION; GLIOMA; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MUTANT; PIK3R1 GENE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PROTEIN MULTIMERIZATION;

ANTINEOPLASTIC AGENTS; HUMANS; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84956633350     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.174     Document Type: Review

References (95)

1. Hoadley KA, Yau C, Wolf DM et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158(4), 929-944 (2014).
2. Weinstein JN, Collisson EA, Mills GB et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat. Genet. 45(10), 1113-1120 (2013).
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002).
4. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl Acad. Sci. USA 104(19), 7809-7814 (2007).
5. Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin. Immunol. 14(1), 7-18 (2002).
6. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481-507 (1998).
7. Yu J, Zhang Y, Mcilroy J, Rordorf-Nikolic T, Orr GA, Backer JM. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18(3), 1379-1387 (1998).
8. Cuevas BD, Lu Y, Mao M et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 276(29), 27455-27461 (2001).
9. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6(3), 184-192 (2006).
10. Foukas LC, Okkenhaug K. Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases. Arch. Biochem. Biophys. 414(1), 13-18 (2003).
11. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006).
12. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2), 104-107 (2007).
13. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21(1), 99-102 (1999).
14. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4(12), 988-1004 (2005).
15. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510 (2008).
16. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36(6), 320-328 (2011).
17. Zabransky DJ, Park BH. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. J. Clin. Oncol. 32(10), 1084-1086 (2014).
18. Kandoth C, Mclellan MD, Vandin F et al. Mutational landscape and significance across 12 major cancer types. Nature 502(7471), 333-339 (2013).
19. Zack TI, Schumacher SE, Carter SL et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45(10), 1134-1140 (2013).
20. Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathwaydirected therapeutic strategies in cancer. Curr. Opin. Invest. Drugs 11(6), 615-628 (2010).
21. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8(8), 627-644 (2009).
22. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10(3), 143-153 (2013).
23. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15(1), 7-24 (2015).
24. Jr. Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 142(2), 164-175 (2014).
25. Wagner AJVHDH, Lorusso PM, Tibes R, Mazina KE, Ware JA. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Presented at: 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, 29 May-2 June 2009.
26. Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy 8(4), 359-367 (2011).
27. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr. Pharm. Des. 18(19), 2766-2777 (2012).
28. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Invest. Drugs 19(11), 1355-1366 (2010).
29. Macias-Perez IM, Flinn IW. G-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep. 8(1), 22-27 (2013).
30. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10(11), 868-880 (2011).
31. Massacesi C, Di Tomaso E, Fretault N, Hirawat S. Challenges in the clinical development of PI3K inhibitors. Ann. NY Acad. Sci. 1280, 19-23 (2013).
32. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 26(25), 3637-3643 (2007).
33. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30 (2004).
34. Martini M, Ciraolo E, Gulluni F, Hirsch E. Targeting PI3K in cancer: any good news? Front. Oncol. 3, 108 (2013).
35. Janku F, Wheler JJ, Naing A et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 73(1), 276-284 (2013).
36. Janku F, Hong DS, Fu S et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 6(2), 377-387 (2014).
37. Cheung LW, Hennessy BT, Li J et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1(2), 170-185 (2011).
38. Kandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 497(7447), 67-73 (2013).
39. Brennan CW, Verhaak RG, Mckenna A et al. The somatic genomic landscape of glioblastoma. Cell 155(2), 462-477 (2013).
40. Cerami E, Gao J, Dogrusoz U et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401-404 (2012).
41. Seshagiri S, Stawiski EW, Durinck S et al. Recurrent R-spondin fusions in colon cancer. Nature 488(7413), 660-664 (2012).
42. Otsu M, Hiles I, Gout I et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 65(1), 91-104 (1991).
43. Miled N, Yan Y, Hon WC et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835), 239-242 (2007).
44. Wu H, Shekar SC, Flinn RJ et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/ p110alpha and are disrupted in oncogenic p85 mutants. Proc. Natl Acad. Sci. USA 106(48), 20258-20263 (2009).
45. Burke JE, Williams RL. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv. Biol. Regul. 53(1), 97-110 (2013).
46. Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc. Natl Acad. Sci. USA 107(35), 15547-15552 (2010).
47. Jaiswal BS, Janakiraman V, Kljavin NM et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16(6), 463-474 (2009).
48. Quayle SN, Lee JY, Cheung LW et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS ONE 7(11), e49466 (2012).
49. Huang CH, Mandelker D, Schmidt-Kittler O et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857), 1744-1748 (2007).
50. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancerspecific mutations in PIK3CA show gain of function. Proc. Natl Acad. Sci. USA 104(13), 5569-5574 (2007).
51. Guillermet-Guibert J, Bjorklof K, Salpekar A et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc. Natl Acad. Sci. USA 105(24), 8292-8297 (2008).
52. Maier U, Babich A, Nurnberg B. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J. Biol. Chem. 274(41), 29311-29317 (1999).
53. Zhang X, Vadas O, Perisic O et al. Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domainmediated inhibitory mechanism. Mol. Cell 41(5), 567-578 (2011).
54. Laurent PA, Severin S, Gratacap MP, Payrastre B. Class I PI 3-kinases signaling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. Adv. Biol. Regul. 54, 162-174 (2014).
55. Garcia Z, Silio V, Marques M et al. A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis. EMBO J. 25(20), 4740-4751 (2006).
56. Chagpar RB, Links PH, Pastor MC et al. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA 107(12), 5471-5476 (2010).
57. Rabinovsky R, Pochanard P, Mcnear C et al. p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol. Cell. Biol. 29(19), 5377-5388 (2009).
58. Yudowski GA, Efendiev R, Pedemonte CH, Katz AI, Berggren PO, Bertorello AM. Phosphoinositide-3 kinase binds to a proline-rich motif in the Na+, K+-ATPase alpha subunit and regulates its trafficking. Proc. Natl Acad. Sci. USA 97(12), 6556-6561 (2000).
59. Barwe SP, Anilkumar G, Moon SY et al. Novel role for Na, K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol. Biol. Cell 16(3), 1082-1094 (2005).
60. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol. Cell. Biol. 22(3), 965-977 (2002).
61. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J. Cell Biol. 170(3), 455-464 (2005).
62. Harpur AG, Layton MJ, Das P et al. Intermolecular interactions of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase. J. Biol. Chem. 274(18), 12323-12332 (1999).
63. Cheung LW, et al. Regulation of the PI3K pathway through a p85? monomer-homodimer equilibrium. Elife. 4, e06866 (2015).
64. Taniguchi CM, Winnay J, Kondo T et al. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res. 70(13), 5305-5315 (2010).
65. Cheung LW, Yu S, Zhang D et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 26(4), 479-494 2014).
66. Ludovini V, Bianconi F, Pistola L et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6(4), 707-715 (2011).
67. Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem. Pharmacol. 90(3), 197-207 (2014).
68. Engelman JA, Mukohara T, Zejnullahu K et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116(10), 2695-2706 (2006).
69. Alimonti A, Carracedo A, Clohessy JG et al. Subtle variations in PTEN dose determine cancer susceptibility. Nat. Genet. 42(5), 454-458 (2010).
70. Davies BR, Greenwood H, Dudley P et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11(4), 873-887 (2012).
71. Li J, Davies BR, Han S et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J. Transl. Med. 11 241 (2013).
72. Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin. Cancer. Res. 19(13), 3533-3544 (2013).
73. Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J. Clin. Oncol. 29(24), 3278-3285 (2011).
74. Mackay HJ, Eisenhauer EA, Kamel-Reid S et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 120(4), 603-610 (2014).
75. Wee S, Wiederschain D, Maira SM et al. PTEN-deficient cancers depend on PIK3CB. Proc. Natl Acad. Sci. USA 105(35), 13057-13062 (2008).
76. Ni J, Liu Q, Xie S et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov. 2(5), 425-433 (2012).
77. Greshock J. Exploiting the synthetic lethal properties of selective PI3K-? inhibition in PTEN deficient cells with GSK2636771. Presented at: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities. Bellevue, WA, USA, 17-20 May 2013.
78. H-T Arkenau, J Mateo, CR Lemech, JR Infante et al. Phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May-3 June 2014.
79. Edgar KA, Wallin JJ, Berry M et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res. 70(3), 1164-1172 (2010).
80. Murga C, Zohar M, Teramoto H, Gutkind JS. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21(2), 207-216 (2002).
81. Ihle NT, Lemos R Jr, Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 69(1), 143-150 (2009).
82. Wee S, Jagani Z, Xiang KX et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69(10), 4286-4293 (2009).
83. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int. J. Cancer 125(10), 2332-2341 (2009).
84. Cizkova M, Vacher S, Meseure D et al. PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer 13, 545 (2013).
85. Lu Y, Lemon W, Liu PY et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 3(12), e467 (2006).
86. Uchino M, Kojima H, Wada K et al. Nuclear betacatenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer 10, 414 (2010).
87. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2(11), 833-849 (2011).
88. Ou O, Huppi K, Chakka S et al. Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer Lett. 354(2), 336-347 2014).
89. Stronach EA, AlfraiDi A, Rama N et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 71(13), 4412-4422 (2011).
90. Hui RC, Francis RE, Guest SK et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther. 7(3), 670-678 (2008).
91. Yang X, Fraser M, Abedini MR, Bai T, Tsang BK. Regulation of apoptosis-inducing factor-mediated, cisplatininduced apoptosis by Akt. Br. J. Cancer 98(4), 803-808 (2008).
92. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67(8), 3626-3636 (2007).
93. Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat. Rev. Clin. Oncol. 9(2), 87-97 (2012).
94. Dimasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87(3), 272-277 (2010).
95. Mills GB. An emerging toolkit for targeted cancer therapies. Genome Res. 22(2), 177-182 (2012).